BACKGROUND: We hypothesized that high-sensitivity cardiac troponin (hs-cTn) and its early change are useful in distinguishing acute myocardial infarction (AMI) from acute cardiac noncoronary artery disease. METHODS AND RESULTS: In a prospective, international multicenter study, hs-cTn was measured with 3 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Siemens) in a blinded fashion at presentation and serially thereafter in 887 unselected patients with acute chest pain. Accuracy of the combination of presentation values with serial changes was compared against a final diagnosis adjudicated by 2 independent cardiologists. AMI was the adjudicated final diagnosis in 127 patients (15%); cardiac noncoronary artery disease, in 124 (14%). Patients with AMI had higher median presentation values of hs-cTnT (0.113 μg/L [interquartile range, 0.049-0.246 μg/L] versus 0.012 μg/L [interquartile range, 0.006-0.034 μg/L]; P<0.001) and higher absolute changes in hs-cTnT in the first hour (0.019 μg/L [interquartile range, 0.007-0.067 μg/L] versus 0.001 μg/L [interquartile range, 0-0.003 μg/L]; P<0.001) than patients with cardiac noncoronary artery disease. Similar findings were obtained with the hs-cTnI assays. Adding changes of hs-cTn in the first hour to its presentation value yielded a diagnostic accuracy for AMI as quantified by the area under the receiver-operating characteristics curve of 0.94 for hs-cTnT (0.92 for both hs-cTnI assays). Algorithms using ST-elevation, presentation values, and changes in hs-cTn in the first hour accurately separated patients with AMI and those with cardiac noncoronary artery disease. These findings were confirmed when the final diagnosis was readjudicated with the use of hs-cTnT values and validated in an independent validation cohort. CONCLUSION: The combined use of hs-cTn at presentation and its early absolute change excellently discriminates between patients with AMI and those with cardiac noncoronary artery disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00470587.
BACKGROUND: We hypothesized that high-sensitivity cardiac troponin (hs-cTn) and its early change are useful in distinguishing acute myocardial infarction (AMI) from acute cardiac noncoronary artery disease. METHODS AND RESULTS: In a prospective, international multicenter study, hs-cTn was measured with 3 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Siemens) in a blinded fashion at presentation and serially thereafter in 887 unselected patients with acute chest pain. Accuracy of the combination of presentation values with serial changes was compared against a final diagnosis adjudicated by 2 independent cardiologists. AMI was the adjudicated final diagnosis in 127 patients (15%); cardiac noncoronary artery disease, in 124 (14%). Patients with AMI had higher median presentation values of hs-cTnT (0.113 μg/L [interquartile range, 0.049-0.246 μg/L] versus 0.012 μg/L [interquartile range, 0.006-0.034 μg/L]; P<0.001) and higher absolute changes in hs-cTnT in the first hour (0.019 μg/L [interquartile range, 0.007-0.067 μg/L] versus 0.001 μg/L [interquartile range, 0-0.003 μg/L]; P<0.001) than patients with cardiac noncoronary artery disease. Similar findings were obtained with the hs-cTnI assays. Adding changes of hs-cTn in the first hour to its presentation value yielded a diagnostic accuracy for AMI as quantified by the area under the receiver-operating characteristics curve of 0.94 for hs-cTnT (0.92 for both hs-cTnI assays). Algorithms using ST-elevation, presentation values, and changes in hs-cTn in the first hour accurately separated patients with AMI and those with cardiac noncoronary artery disease. These findings were confirmed when the final diagnosis was readjudicated with the use of hs-cTnT values and validated in an independent validation cohort. CONCLUSION: The combined use of hs-cTn at presentation and its early absolute change excellently discriminates between patients with AMI and those with cardiac noncoronary artery disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00470587.
Authors: Tobias Reichlin; Raphael Twerenbold; Karin Wildi; Maria Rubini Gimenez; Nathalie Bergsma; Philip Haaf; Sophie Druey; Christian Puelacher; Berit Moehring; Michael Freese; Claudia Stelzig; Lian Krivoshei; Petra Hillinger; Cedric Jäger; Thomas Herrmann; Philip Kreutzinger; Milos Radosavac; Zoraida Moreno Weidmann; Kateryna Pershyna; Ursina Honegger; Max Wagener; Thierry Vuillomenet; Isabel Campodarve; Roland Bingisser; Òscar Miró; Katharina Rentsch; Stefano Bassetti; Stefan Osswald; Christian Mueller Journal: CMAJ Date: 2015-04-13 Impact factor: 8.262
Authors: Christopher Layfield; John Rose; Aaron Alford; Susan R Snyder; Fred S Apple; Farah M Chowdhury; Michael C Kontos; L Kristin Newby; Alan B Storrow; Milenko Tanasijevic; Elizabeth Leibach; Edward B Liebow; Robert H Christenson Journal: Clin Biochem Date: 2015-02-07 Impact factor: 3.281
Authors: Ivo Strebel; Raphael Twerenbold; Jasper Boeddinghaus; Roger Abächerli; Maria Rubini Giménez; Karin Wildi; Karin Grimm; Christian Puelacher; Patrick Badertscher; Zaid Sabti; Dominik Breitenbücher; Janina Jann; Farah Selman; Jeanne du Fay de Lavallaz; Nicolas Schaerli; Thomas Nestelberger; Claudia Stelzig; Michael Freese; Lukas Schumacher; Stefan Osswald; Christian Mueller; Tobias Reichlin Journal: Ann Noninvasive Electrocardiol Date: 2018-02-24 Impact factor: 1.468